NCT01731340

Brief Summary

The overarching aim of this randomized clinical trial is to estimate the effect of dietary intake of calcium as compared to supplemental calcium on the vascular system and markers of vascular and bone health in postmenopausal women.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
123

participants targeted

Target at P50-P75 for phase_4 cardiovascular-diseases

Timeline
Completed

Started Jun 2012

Longer than P75 for phase_4 cardiovascular-diseases

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2012

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

November 16, 2012

Completed
5 days until next milestone

First Posted

Study publicly available on registry

November 21, 2012

Completed
6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 14, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 14, 2018

Completed
Last Updated

September 18, 2019

Status Verified

September 1, 2019

Enrollment Period

6.5 years

First QC Date

November 16, 2012

Last Update Submit

September 16, 2019

Conditions

Keywords

Calcium SupplementsDairy FoodsCardiovascular DiseasesOsteoporosisPostmenopauseVitamin DMicronutrientsPrimary PreventionBone Health

Outcome Measures

Primary Outcomes (1)

  • Vascular System

    Measured as changes in: * Arterial stiffness (carotid-femoral pulse wave velocity) * Arterial wall thickness (carotid intima-media thickness)

    12 months

Secondary Outcomes (1)

  • Hemodynamics

    12 Months

Other Outcomes (3)

  • Blood Biomarkers

    12 months

  • Anthropomorphic measurements

    12 months

  • Adverse Events

    12 months

Study Arms (3)

Supplemental Calcium

ACTIVE COMPARATOR

* 750 mg Calcium Citrate per day * 800 IU Vitamin D3 per day * Low Dietary Calcium (450 mg per day)

Dietary Supplement: Calcium CitrateOther: Low Dietary Calcium

Dietary Calcium

ACTIVE COMPARATOR

* 400 IU Vitamin D3 per day * High Dietary Calcium (1200 mg per day)

Other: High Dietary Calcium

Usual Diet

NO INTERVENTION

* 400 IU Vitamin D3 per day * Unrestricted Dietary Calcium

Interventions

Calcium CitrateDIETARY_SUPPLEMENT

750mg

Supplemental Calcium

450 mg

Supplemental Calcium

1200 mg

Dietary Calcium

Eligibility Criteria

Age50 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Women aged 50 or more
  • years since last menstrual period
  • Body Mass Index between 20 and 35 kg/m2

You may not qualify if:

  • Atrial Fibrillation
  • Coronary artery disease
  • Myocardial infarction
  • Stroke
  • Transient ischaemic attack
  • Peripheral vascular disease
  • Sleep apnea
  • Hypertension
  • Hyperlipidemia
  • Hyperparathyroidism
  • Urinary tract lithiasis
  • Rheumatoid arthritis
  • Crohn's disease
  • Ulcerative colitis
  • Short gut syndrome
  • +12 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Internal Medicine; Montreal General Hospital

Montreal, Quebec, H3G 1A4, Canada

Location

MeSH Terms

Conditions

Cardiovascular DiseasesOsteoporosis

Interventions

Calcium Citrate

Condition Hierarchy (Ancestors)

Bone Diseases, MetabolicBone DiseasesMusculoskeletal DiseasesMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Calcium CompoundsInorganic ChemicalsCitric AcidCitratesTricarboxylic AcidsAcids, AcyclicCarboxylic AcidsOrganic Chemicals

Study Officials

  • Suzanne Morin, MD MSc

    McGill University Hospital Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD MSc FRCP

Study Record Dates

First Submitted

November 16, 2012

First Posted

November 21, 2012

Study Start

June 1, 2012

Primary Completion

November 14, 2018

Study Completion

November 14, 2018

Last Updated

September 18, 2019

Record last verified: 2019-09

Data Sharing

IPD Sharing
Will not share

Locations